BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 33815377)

  • 1. Expansion of Functional Myeloid-Derived Suppressor Cells in Controlled Human Malaria Infection.
    Lamsfus Calle C; Fendel R; Singh A; Richie TL; Hoffman SL; Kremsner PG; Mordmüller B
    Front Immunol; 2021; 12():625712. PubMed ID: 33815377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection.
    Lyke KE; Ishizuka AS; Berry AA; Chakravarty S; DeZure A; Enama ME; James ER; Billingsley PF; Gunasekera A; Manoj A; Li M; Ruben AJ; Li T; Eappen AG; Stafford RE; Kc N; Murshedkar T; Mendoza FH; Gordon IJ; Zephir KL; Holman LA; Plummer SH; Hendel CS; Novik L; Costner PJ; Saunders JG; Berkowitz NM; Flynn BJ; Nason MC; Garver LS; Laurens MB; Plowe CV; Richie TL; Graham BS; Roederer M; Sim BK; Ledgerwood JE; Hoffman SL; Seder RA
    Proc Natl Acad Sci U S A; 2017 Mar; 114(10):2711-2716. PubMed ID: 28223498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of human Pegivirus infections in whole Plasmodium falciparum sporozoite vaccination and controlled human malaria infection in African volunteers.
    Tumbo AM; Schindler T; Dangy JP; Orlova-Fink N; Bieri JR; Mpina M; Milando FA; Juma O; Hamad A; Nyakarungu E; Chemba M; Mtoro A; Ramadhan K; Olotu A; Makweba D; Mgaya S; Stuart K; Perreau M; Stapleton JT; Jongo S; Hoffman SL; Tanner M; Abdulla S; Daubenberger C
    Virol J; 2021 Jan; 18(1):28. PubMed ID: 33499880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine.
    Mordmüller B; Surat G; Lagler H; Chakravarty S; Ishizuka AS; Lalremruata A; Gmeiner M; Campo JJ; Esen M; Ruben AJ; Held J; Calle CL; Mengue JB; Gebru T; Ibáñez J; Sulyok M; James ER; Billingsley PF; Natasha KC; Manoj A; Murshedkar T; Gunasekera A; Eappen AG; Li T; Stafford RE; Li M; Felgner PL; Seder RA; Richie TL; Sim BK; Hoffman SL; Kremsner PG
    Nature; 2017 Feb; 542(7642):445-449. PubMed ID: 28199305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection.
    Murphy SC; Deye GA; Sim BKL; Galbiati S; Kennedy JK; Cohen KW; Chakravarty S; Kc N; Abebe Y; James ER; Kublin JG; Hoffman SL; Richie TL; Jackson LA
    PLoS Pathog; 2021 May; 17(5):e1009594. PubMed ID: 34048504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of
    Jongo SA; Shekalaghe SA; Church LWP; Ruben AJ; Schindler T; Zenklusen I; Rutishauser T; Rothen J; Tumbo A; Mkindi C; Mpina M; Mtoro AT; Ishizuka AS; Kassim KR; Milando FA; Qassim M; Juma OA; Mwakasungula S; Simon B; James ER; Abebe Y; Kc N; Chakravarty S; Saverino E; Bakari BM; Billingsley PF; Seder RA; Daubenberger C; Sim BKL; Richie TL; Tanner M; Abdulla S; Hoffman SL
    Am J Trop Med Hyg; 2018 Aug; 99(2):338-349. PubMed ID: 29943719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.
    Ishizuka AS; Lyke KE; DeZure A; Berry AA; Richie TL; Mendoza FH; Enama ME; Gordon IJ; Chang LJ; Sarwar UN; Zephir KL; Holman LA; James ER; Billingsley PF; Gunasekera A; Chakravarty S; Manoj A; Li M; Ruben AJ; Li T; Eappen AG; Stafford RE; K C N; Murshedkar T; DeCederfelt H; Plummer SH; Hendel CS; Novik L; Costner PJ; Saunders JG; Laurens MB; Plowe CV; Flynn B; Whalen WR; Todd JP; Noor J; Rao S; Sierra-Davidson K; Lynn GM; Epstein JE; Kemp MA; Fahle GA; Mikolajczak SA; Fishbaugher M; Sack BK; Kappe SH; Davidson SA; Garver LS; Björkström NK; Nason MC; Graham BS; Roederer M; Sim BK; Hoffman SL; Ledgerwood JE; Seder RA
    Nat Med; 2016 Jun; 22(6):614-23. PubMed ID: 27158907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.
    Dejon-Agobe JC; Ateba-Ngoa U; Lalremruata A; Homoet A; Engelhorn J; Nouatin OP; Edoa JR; Fernandes JF; Esen M; Mouwenda YD; Betouke Ongwe EM; Massinga-Loembe M; Hoffman SL; Sim BKL; Theisen M; Kremsner PG; Adegnika AA; Lell B; Mordmüller B
    Clin Infect Dis; 2019 Sep; 69(8):1377-1384. PubMed ID: 30561539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-Dependent Infectivity of Aseptic, Purified, Cryopreserved Plasmodium falciparum 7G8 Sporozoites in Malaria-Naive Adults.
    Laurens MB; Berry AA; Travassos MA; Strauss K; Adams M; Shrestha B; Li T; Eappen A; Manoj A; Abebe Y; Murshedkar T; Gunasekera A; Richie TL; Lyke KE; Plowe CV; Kennedy JK; Potter GE; Deye GA; Sim BKL; Hoffman SL
    J Infect Dis; 2019 Nov; 220(12):1962-1966. PubMed ID: 31419294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial.
    Sulyok Z; Fendel R; Eder B; Lorenz FR; Kc N; Karnahl M; Lalremruata A; Nguyen TT; Held J; Adjadi FAC; Klockenbring T; Flügge J; Woldearegai TG; Lamsfus Calle C; Ibáñez J; Rodi M; Egger-Adam D; Kreidenweiss A; Köhler C; Esen M; Sulyok M; Manoj A; Richie TL; Sim BKL; Hoffman SL; Mordmüller B; Kremsner PG
    Nat Commun; 2021 May; 12(1):2518. PubMed ID: 33947856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of CD4+CD45RO+ T lymphocytes producing IL-4 in response to antigens on Plasmodium falciparum erythrocytes: an in vitro correlate of protective immunity induced with attenuated Plasmodium falciparum sporozoites.
    Bergmann ES; Ballou RW; Krzych U
    Cell Immunol; 1997 Sep; 180(2):143-52. PubMed ID: 9341744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection.
    Sulyok M; Rückle T; Roth A; Mürbeth RE; Chalon S; Kerr N; Samec SS; Gobeau N; Calle CL; Ibáñez J; Sulyok Z; Held J; Gebru T; Granados P; Brückner S; Nguetse C; Mengue J; Lalremruata A; Sim BKL; Hoffman SL; Möhrle JJ; Kremsner PG; Mordmüller B
    Lancet Infect Dis; 2017 Jun; 17(6):636-644. PubMed ID: 28363637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates.
    Gómez-Pérez GP; Legarda A; Muñoz J; Sim BK; Ballester MR; Dobaño C; Moncunill G; Campo JJ; Cisteró P; Jimenez A; Barrios D; Mordmüller B; Pardos J; Navarro M; Zita CJ; Nhamuave CA; García-Basteiro AL; Sanz A; Aldea M; Manoj A; Gunasekera A; Billingsley PF; Aponte JJ; James ER; Guinovart C; Antonijoan RM; Kremsner PG; Hoffman SL; Alonso PL
    Malar J; 2015 Aug; 14():306. PubMed ID: 26245196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The march toward malaria vaccines.
    Hoffman SL; Vekemans J; Richie TL; Duffy PE
    Vaccine; 2015 Nov; 33 Suppl 4(Suppl 4):D13-23. PubMed ID: 26324116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic markers associate with protection against malaria in human volunteers immunized with Plasmodium falciparum sporozoites.
    Bijker EM; Teirlinck AC; Schats R; van Gemert GJ; van de Vegte-Bolmer M; van Lieshout L; IntHout J; Hermsen CC; Scholzen A; Visser LG; Sauerwein RW
    J Infect Dis; 2014 Nov; 210(10):1605-15. PubMed ID: 24872326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres.
    Mordmüller B; Supan C; Sim KL; Gómez-Pérez GP; Ospina Salazar CL; Held J; Bolte S; Esen M; Tschan S; Joanny F; Lamsfus Calle C; Löhr SJ; Lalremruata A; Gunasekera A; James ER; Billingsley PF; Richman A; Chakravarty S; Legarda A; Muñoz J; Antonijoan RM; Ballester MR; Hoffman SL; Alonso PL; Kremsner PG
    Malar J; 2015 Mar; 14():117. PubMed ID: 25889522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1.
    Roestenberg M; Walk J; van der Boor SC; Langenberg MCC; Hoogerwerf MA; Janse JJ; Manurung M; Yap XZ; García AF; Koopman JPR; Meij P; Wessels E; Teelen K; van Waardenburg YM; van de Vegte-Bolmer M; van Gemert GJ; Visser LG; van der Ven AJAM; de Mast Q; Natasha KC; Abebe Y; Murshedkar T; Billingsley PF; Richie TL; Sim BKL; Janse CJ; Hoffman SL; Khan SM; Sauerwein RW
    Sci Transl Med; 2020 May; 12(544):. PubMed ID: 32434847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: a review.
    Epstein JE; Richie TL
    Curr Opin Infect Dis; 2013 Oct; 26(5):420-8. PubMed ID: 23982233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring immunological mechanisms of the whole sporozoite vaccination against P. falciparum malaria.
    Mo AX; Pesce J; Hall BF
    Vaccine; 2015 Jun; 33(25):2851-7. PubMed ID: 25917675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines.
    Richie TL; Billingsley PF; Sim BK; James ER; Chakravarty S; Epstein JE; Lyke KE; Mordmüller B; Alonso P; Duffy PE; Doumbo OK; Sauerwein RW; Tanner M; Abdulla S; Kremsner PG; Seder RA; Hoffman SL
    Vaccine; 2015 Dec; 33(52):7452-61. PubMed ID: 26469720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.